KALA BIO (KALA)

• Market cap: $32M
• 1 day: 11.38%
• 5 days: 19.83%
• 1 month: 7.09%
• 3 months: 32.38%
• 6 months: 51.09%
• Year to date: 0.00%
• 1 year: -8.67%
• 5 years: -96.32%
• 10 years: -99.25%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Employees: 43

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

7% less funds holding

Funds holding: 29 [Q2] → 27 (-2) [Q3]

19% less capital invested

Capital invested by funds: $14.8M [Q2] → $12.1M (-$2.77M) [Q3]

28.29% less ownership

Funds ownership: 74.22% [Q2] → 45.92% (-28.29%) [Q3]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 116% upside
• Avg. target: $15 116% upside
• High target: $15 116% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 40% 1-year accuracy 62 / 155 met price target

116% upside $15

Buy Reiterated

15 Nov 2024